title: Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study.
abstract: Hepatitis C virus (HCV)-infection can cause hepatocellular carcinoma (HCC) and most likely non-Hodgkin lymphoma (NHL). No studies have compared the risk of these cancers between patients with chronic and cleared HCV-infection. The aim of this study was to estimate the 10-year risk of HCC and NHL in HCV-infected patients and to compare the risk of these cancers between HCV-infected patients and the general population in Denmark and between patients with chronic and cleared HCV-infection. Nationwide cohorts were used: 11,975 HCV-infected patients in the DANVIR cohort and 71,850 individuals from an age- and gender-matched general population cohort. Within DANVIR, 4,158 patients with chronic HCV-infection and 2,427 patients with cleared HCV-infection were studied. The 10-year risks of HCC and NHL in HCV-infected patients were 1.0% [95% confidence interval (CI): 0.8-1.3%] and 0.1% (95% CI: 0.1-0.2%), respectively. Compared to the general population, HCV-infected patients had a 62.91-fold increased risk of HCC (95% CI: 28.99-136.52), a 29.97-fold increased risk of NHL during the first year of follow-up (95% CI: 6.08-147.84), and a 1.26-fold increased risk of NHL after the first year (95% CI: 0.36-4.41). Chronic HCV-infection was associated with a 4.71-fold increased risk of HCC (95% CI: 1.67-13.32) compared to cleared HCV-infection; 5 and 0 events of NHL occurred in patients with chronic and cleared HCV-infection, respectively. HCC-risk is increased substantially in HCV-infected patients compared to the general population. Chronic as opposed to cleared HCV-infection increases the risk of HCC and perhaps NHL.
authors.affiliation: Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark. omland@dadlnet.dk
authors.forename: Lars Haukali
authors.initials: LH
authors.lastname: Omland
authors.forename: Peter
authors.initials: P
authors.lastname: Jepsen
authors.forename: Henrik
authors.initials: H
authors.lastname: Krarup
authors.forename: Peer Brehm
authors.initials: PB
authors.lastname: Christensen
authors.forename: Nina
authors.initials: N
authors.lastname: Weis
authors.forename: Lars
authors.initials: L
authors.lastname: Nielsen
authors.forename: Niels
authors.initials: N
authors.lastname: Obel
authors.forename: Henrik Toft
authors.initials: HT
authors.lastname: Sørensen
authors.forename: Sherri Oliver
authors.initials: SO
authors.lastname: Stuver
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000150:complications* / Q000453:epidemiology; D002648:Child; D015331:Cohort Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications* / Q000453:epidemiology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012306:Risk
chemical_list: D018937:Hepatitis C Antibodies